tradingkey.logo

Novo Nordisk To Acquire Akero Therapeutics

ReutersOct 9, 2025 10:04 AM

- Novo Nordisk NOVOb.CO:

  • TO ACQUIRE AKERO THERAPEUTICS AND ITS PROMISING PHASE 3 FGF21 ANALOGUE TO EXPAND MASH PORTFOLIO

  • TO BUY AKERO FOR $4.7 BILLION IN CASH

  • AKERO'S EFRUXIFERMIN SHOWS SIGNIFICANT FIBROSIS REGRESSION IN PHASE 2

  • AKERO BOARD APPROVES DEAL, EXPECTED TO CLOSE YEAR-END

  • DEAL NOT EXPECTED TO IMPACT NOVO NORDISK'S 2025 PROFIT OUTLOOK

  • 2025 FREE CASH FLOW OUTLOOK NEGATIVELY IMPACTED BY $4 BILLION

  • FOR 2026, ACQUISITION IS EXPECTED TO LEAD TO INCREASED RESEARCH AND DEVELOPMENT T COSTS

  • NEGATIVE IMPACT ON FY OPERATING PROFIT GROWTH IN 2026 OF AROUND 3%-POINTS

  • IMPLIED 2025 FREE CASH FLOW OUTLOOK IS THEREFORE 9-19 BILLION DKK DEPENDING ON TIMING OF CLOSING

  • 2026 PROFIT GROWTH IMPACTED BY 3%-POINTS DUE TO RESEARCH AND DEVELOPMENT COSTS

  • TRANSACTION WILL BE MAINLY DEBT FINANCED

Further company coverage: NOVOb.CO

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI